Genomics, Biotechnology, and the UAE Longevity Strategy
When the UAE leadership articulates the Centennial 2071 vision, the language consistently returns to one concept that underpins all others: the quality of human life. A nation cannot sustain a hundred-year space programme, an AI-driven economy, or a world-class education system if its citizens are not healthy enough to contribute across their full lifespans. The UAE’s investment in genomics, biotechnology, and what officials increasingly describe as a “national longevity strategy” reflects this understanding. By 2071, the goal is not merely a nation that is wealthier or more technologically advanced, but one that is fundamentally healthier — with life expectancy among the highest in the world and healthcare costs radically reduced through prevention rather than treatment.
The Emirati Genome Programme
The foundation of the UAE’s biotech ambitions is the Emirati Genome Programme, one of the most ambitious national genomics initiatives outside the United Kingdom, Iceland, and China. Launched in its current form in 2021 under the Department of Health Abu Dhabi and coordinated by Group 42 (G42), the programme aims to sequence the genomes of the entire Emirati citizen population — approximately 1.2 million individuals.
The strategic logic is straightforward. The Emirati population, due to historically high rates of consanguineous marriage (estimated at 40-50% of marriages among Emirati nationals), carries an elevated prevalence of certain genetic conditions including thalassemia, sickle cell disease, cystic fibrosis, and specific forms of hereditary diabetes and cardiovascular disease. A comprehensive genomic database enables population-level screening, carrier identification, genetic counselling, and — eventually — gene therapy and pharmacogenomic interventions tailored to the Emirati genetic profile.
G42 Healthcare, the biotech subsidiary of Abu Dhabi’s G42, operates the genomic sequencing infrastructure. The company’s Omics Centre of Excellence in Abu Dhabi houses one of the largest sequencing facilities in the Middle East, capable of processing thousands of whole genome sequences per month using Illumina and Oxford Nanopore platforms. As of late 2025, over 600,000 Emirati genomes have been sequenced, placing the programme on track for completion by 2028.
The data generated by the programme is stored in a sovereign health data platform governed by Abu Dhabi’s Department of Health, with strict privacy protections modelled on European GDPR standards. The platform enables researchers — subject to ethics committee approval — to conduct population-level studies on disease prevalence, genetic risk factors, and treatment outcomes. The long-term vision is a national health system in which every Emirati citizen’s medical care is informed by their individual genomic profile.
Precision Medicine: From Population Genomics to Personalised Treatment
The genome programme is the data layer. Precision medicine is the clinical layer. The UAE’s strategy envisions a healthcare system that moves from reactive, symptom-based treatment to proactive, genomic-informed prevention. This shift has profound implications for healthcare costs, quality of life, and economic productivity.
Cleveland Clinic Abu Dhabi, one of the UAE’s flagship healthcare institutions, has established a precision medicine programme that integrates genomic data with clinical care. Patients with hereditary cancer syndromes, cardiovascular genetic conditions, or rare diseases can now receive treatment plans informed by their genetic variants — matching therapies to molecular profiles rather than applying one-size-fits-all protocols.
The Abu Dhabi Stem Cell Centre, established in 2019, conducts research on regenerative medicine, cell therapy, and tissue engineering. During the COVID-19 pandemic, the centre developed a pioneering nebulised stem cell treatment that received emergency use authorisation and was administered to critically ill patients. This institutional capacity — the ability to rapidly develop and deploy novel biological therapies — is a core competency that the Centennial strategy aims to expand.
Pharmacogenomics, the study of how genes affect individual responses to medications, is being integrated into the national health system. The goal is that by 2035, all medications prescribed to Emirati patients will be informed by pharmacogenomic data — optimising drug selection, dosing, and timing to maximise efficacy and minimise adverse reactions. The economic impact is significant: adverse drug reactions account for approximately 5-10% of hospital admissions globally and represent billions of dollars in healthcare costs.
The Longevity Agenda
The UAE’s interest in longevity extends beyond conventional healthcare. The country is positioning itself as a hub for longevity science — the multidisciplinary field that combines genomics, epigenetics, senolytics, nutritional science, and regenerative medicine to extend healthy human lifespan.
The concept of “healthspan” — the number of years lived in good health, as distinct from total lifespan — is central to the UAE’s approach. Average life expectancy in the UAE has risen from 63 years in 1971 to approximately 78 years in 2025, a remarkable improvement. But the Centennial 2071 target is not merely to extend life but to extend healthy life — compressing the period of age-related decline and disability into the shortest possible window at the end of life.
Dubai Future Foundation, through its research arm, has published white papers on longevity science and its implications for national strategy. Abu Dhabi’s Hub71 technology ecosystem has attracted several longevity-focused startups, including companies working on senolytics (drugs that clear senescent cells), NAD+ restoration, and AI-driven aging biomarker analysis.
The economic case for longevity investment is compelling. An Emirati population that remains healthy and productive into their 70s and 80s generates more economic output, requires less healthcare expenditure, and contributes more to the social fabric of the nation. In a country with a small citizen population, every healthy year of contribution from every citizen carries outsized economic significance.
Biotechnology Industry Development
Beyond healthcare applications, the UAE is developing a commercial biotechnology sector that can serve as an economic diversification vehicle. The Abu Dhabi Economic Vision 2030 identified life sciences as a priority sector, and subsequent investments have built the institutional infrastructure.
Khalifa University’s biotechnology programme, the Masdar Institute’s bio-engineering research, and the establishment of specialised bio-incubators in Abu Dhabi’s Innovation District are creating a pipeline of local biotech ventures. The regulatory framework, overseen by the Department of Health Abu Dhabi and the Emirates Health Services, is being modernised to accommodate clinical trials, gene therapy regulation, and biosecurity oversight.
The agri-biotech subsector deserves particular mention. The UAE imports approximately 90% of its food, a vulnerability that the Centennial strategy seeks to reduce. Biotech approaches to food security — including genetically modified crops adapted to arid environments, vertical farming with bio-optimised growth media, cultured meat production, and marine aquaculture using genetically improved fish stocks — are being pursued through both government research programmes and private sector investment.
The International Centre for Biosaline Agriculture (ICBA), headquartered in Dubai, conducts research on salt-tolerant crops and sustainable agriculture in marginal environments. Its work has global relevance — the techniques developed for UAE conditions are applicable to any arid or saline agricultural zone — and positions the UAE as a knowledge exporter in climate-adapted agriculture.
Data Infrastructure and AI Integration
The convergence of genomics data, electronic health records, medical imaging, and wearable device data creates extraordinary opportunities for AI-driven health insights. The UAE’s parallel investments in AI infrastructure (MBZUAI, G42, sovereign compute) and health data (the Genome Programme, Malaffi health information exchange) position the country uniquely to develop AI-powered health applications.
Malaffi, the Abu Dhabi health information exchange platform, connects all healthcare providers in the emirate — public and private — into a single data ecosystem. This means that a patient’s complete medical history, including genomic data, lab results, imaging, prescriptions, and clinical notes, is accessible to any authorised provider. The dataset is anonymised and made available to approved researchers, creating one of the most comprehensive health data repositories in the Middle East.
The application of machine learning to this dataset is already yielding results. Predictive models for diabetes onset, cardiovascular event risk, and cancer screening optimisation are in various stages of development and clinical validation. By 2071, the vision is a health system in which AI continuously monitors population health trends, identifies emerging disease clusters, personalises prevention programmes, and optimises resource allocation across the entire healthcare system in real time.
Mental Health and Wellbeing
The Centennial 2071 strategy’s emphasis on quality of life extends explicitly to mental health and psychological wellbeing. The UAE has made significant progress in destigmatising mental health — historically a taboo subject in Gulf societies — through public awareness campaigns, the integration of mental health services into primary care, and the establishment of dedicated mental health facilities.
The National Programme for Happiness and Wellbeing, a cabinet-level initiative, tracks citizen wellbeing using surveys, behavioural data, and community engagement metrics. The programme’s integration into the Centennial framework reflects the understanding that a technologically advanced, economically diversified, highly educated society is not a successful society if its citizens are not psychologically thriving.
Workplace mental health programmes, school-based counselling services, and digital mental health platforms (including AI-powered chatbots for initial screening and support) are being scaled across the country. The target is a comprehensive mental health ecosystem that is as accessible and unstigmatised as physical healthcare.
Regulatory and Ethical Frameworks
The rapid advancement of genomics and biotechnology raises ethical questions that the UAE is addressing proactively. The UAE Bioethics Advisory Committee provides guidance on issues including genetic privacy, informed consent for genomic sequencing, the ethical boundaries of gene editing, and the regulation of human embryo research.
The country’s position on gene editing — cautious but open to therapeutic applications — contrasts with more restrictive approaches in some European jurisdictions and more permissive approaches in parts of Asia. The regulatory framework is being developed in consultation with international bodies including the World Health Organisation and the Global Alliance for Genomics and Health.
Data sovereignty is a particular priority. The Emirati genome data is stored within the UAE, governed by UAE law, and not shared with foreign governments or commercial entities without explicit authorisation. This sovereign approach to health data governance — maintaining national control over the most intimate category of personal data — reflects broader UAE principles about digital sovereignty and national security.
The 2071 Health Landscape
By 2071, if the current investment trajectory continues, the UAE envisions a healthcare system that is predictive (identifying disease before symptoms appear), personalised (tailored to individual genetic profiles), preventive (emphasising lifestyle and environmental interventions over treatment), and participatory (engaging citizens as active partners in their own health management).
Life expectancy targets for 2071, while not officially published, are implied by the strategy’s trajectory. If the current rate of improvement continues and is accelerated by genomic medicine and longevity science, Emirati life expectancy could approach or exceed 90 years — with the majority of those years lived in active, productive health.
Conclusion
The UAE’s investment in genomics, biotechnology, and longevity science is the most personal dimension of the Centennial 2071 vision. While the space programme captures headlines and the AI strategy commands boardroom attention, it is the health transformation that will most directly affect the lives of every Emirati citizen. A nation that is healthier, longer-lived, and supported by a precision medicine infrastructure that is among the most advanced in the world — this is the human foundation upon which all other Centennial ambitions rest. The genome programme is the dataset. Precision medicine is the application. Longevity science is the horizon. Together, they represent the UAE’s most intimate commitment to the wellbeing of its people across the next half-century.